Journal of
Public Health and Epidemiology

  • Abbreviation: J. Public Health Epidemiol.
  • Language: English
  • ISSN: 2141-2316
  • DOI: 10.5897/JPHE
  • Start Year: 2009
  • Published Articles: 511

Full Length Research Paper

Alarming levels of ototoxicity among multidrug resistant tuberculosis patients on intensive phase of treatment at specialist treatment centers in South Western, Nigeria

Bamgboye Eniola Adetola
Department of Epidemiology and Medical Statistics, Faculty of Public Health, College of Medicine, University of Ibadan, Ibadan, Nigeria.
Email: [email protected]

  •  Received: 25 March 2019
  •  Accepted: 12 July 2019
  •  Published: 30 September 2019

References

Avong YK, Isaakidis P, Hinderaker SG, Van den Bergh R, Ali E, Obembe BO, Dakum PS (2015). Doing no harm? Adverse events in a nation-wide cohort of patients with multidrug-resistant tuberculosis in Nigeria. PLoS One 10(3):e0120161.
Crossref
 
Black RE, Lau WK, Weinstein RJ, Young LS, Hewitt WL (1976). Ototoxicity of amikacin. Antimicrobial Agents Chemotherapy 9(6):956-961.
Crossref
 
de Jager P, van Altena R (2002). Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis. International Journal of Tuberculosis and Lung Dieaase 6(7):622-627.
 
Duggal P, Sarkar M (2007). Audiologic monitoring of multi-drug resistant tuberculosis patients on aminoglycoside treatment with long term follow-up. BMC Ear Nose Throat Disorder 7:5.
Crossref
 
Fausti SA, Henry JA, Schaffer HI, Olson DJ, Frey RH, McDonald WJ (1992). High-frequency audiometric monitoring for early detection of aminoglycoside ototoxicity. Journal of Infectious Disease 165(6):1026-1032.
Crossref
 
Ganesan P, Schmiedge J, Manchaiah V, Swapna S, Dhandayutham S, Kothandaraman PP (2018). Ototoxicity: A Challenge in Diagnosis and Treatment. Journal of Audiology and Otology 22(2):59-68.
Crossref
 
Harris T, Bardien S, Schaaf HS, Petersen L, De Jong G, Fagan JJ (2012). Aminoglycoside-induced hearing loss in HIV-positive and HIV-negative multidrug-resistant tuberculosis patients. South African Medical Journal 102(6).
Crossref
 
Hawkins JE (1976). Drug ototoxicity. Handbook of sensory physiology 5:707-748.
Crossref
 
Hong H, Budhathoki C, Farley JE (2018). Increased risk of aminoglycoside-induced hearing loss in MDR-TB patients with HIV coinfection. International Journal of Tuberculosis Lung Disease 22(6):667-674.
Crossref
 
Ibekwe M, Nwosu C (2016). Pure tone audiometric findings in patients on second-line treatment for multidrug-resistant tuberculosis. Port Harcourt Medical Journal 10(3):97-101.
Crossref
 
Kurbatova EV, Cegielski JP, Lienhardt C, Akksilp R, Bayona J, Becerra MC, Zignol M (2015). Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies. Lancet Respiratory Medical 3(3):201-209.
Crossref
 
Modongo C, Sobota RS, Kesenogile B, Ncube R, Sirugo G, Williams SM, Zetola NM (2014). Successful MDR-TB treatment regimens including Amikacin are associated with high rates of hearing loss. BMC Infectious Diseases 14(1):542.
Crossref
 
Schnippel K, Berhanu RH, Black A, Firnhaber C, Maitisa N, Evans D, Sinanovic E (2016). Severe adverse events during second-line tuberculosis treatment in the context of high HIV Co-infection in South Africa: a retrospective cohort study. BMC Infectious Diseases 16(1):593.
Crossref
 
Sharma V, Bhagat S, Verma B, Singh R, Singh S (2016). Audiological Evaluation of Patients Taking Kanamycin for Multidrug Resistant Tuberculosis. Iranian Journal of Otorhinolaryngology 28(86):203-208.
 
Sogebi OA, Adefuye BO, Adebola SO, Oladeji SM, Adedeji TO (2017). Clinical predictors of aminoglycoside-induced ototoxicity in drug-resistant Tuberculosis patients on intensive therapy. Auris Nasus Larynx 44(4):404-410.
Crossref
 
Sturdy A, Goodman A, José RJ, Loyse A, O'Donoghue M, Kon OM, Cooke GS (2011). Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice. Journal of Antimicrobial Chemotherapy 66(8):1815-1820.
Crossref
 
Torun T, Gungor G, Ozmen I, Bolukbasi Y, Maden E, Bicakci B, Tahaoglu K(2005). Side effects associated with the treatment of multidrug-resistant tuberculosis. International Journal of Tuberculosis and Lung Disease 9(12):1373-1377.
 
Vakulenko SB and Mobashery S (2003). Versatility of Aminoglycosides and Prospects for Their Future. Clinical Microbiology Reviews, 16(3):430-450.
Crossref
 

World Health Organization (WHO) (2016). WHO drug treatment guidelines for drug resistant tuberculosis.

View

 
Yang TW, Park HO, Jang HN, Yang JH, Kim SH. Moon SH, Kang DH (2017). Side effects associated with the treatment of multidrug-resistant tuberculosis at a tuberculosis referral hospital in South Korea: A retrospective study. Medicine (Baltimore) 96(28):e7482.
Crossref